AAV Capsid Development

Custom AAV Capsid Development

Engineered by us. Tailored for you.

Delivering the therapeutic payload to the right target tissue, organ or cell is crucial for the success of your gene therapy. Yet adeno-associated virus (AAV) engineering and development can be challenging, requiring significant investment, expertise and innovation. Collaborate with Revvity's gene delivery team, formerly SIRION Biotech, to benefit from many years of experience and innovation in AAV capsid engineering and development to help accelerate your gene therapy's journey to the clinic.

Your innovation partner for AAV development

We have a track record of innovation in AAV development and approaches. Partner with us to stay at the forefront of AAV engineering, and to work with the experts who are shaping its future.

And with no competing therapeutic pipeline, you can be confident that we are fully dedicated to developing the novel adeno-associated viral vectors you need.

You can benefit from:

Reduced timelines: Pre-enriched materials, established processes and partnership networks all contribute to a shortened development path.
Novel variants: Our broad library of optimized inputs increases the potential of identifying variants with improved performance.
Financial flexibility: Outsource your AAV development project to our dedicated team for greater flexibility of your resources.
Our expertise: Partner with our expert team to benefit from over a decade of experience, innovation, and a strong partnership network.

1000+ de novo batches of AAV manufactured

500+ novel AAVs created and evaluated

10+ years of experience in AAV vector projects with professional alliance management

Enhanced AAV capsid directed evolution

Our tailored and unbiased de novo approach to capsid randomization is based on proven peptide display and DNA shuffling, and iterative screening in NHP.

Pre-enriched libraries for major target organs to help optimize costs and shorten your development timelines
Reducing off-targeting effects with pre-selecting variants with reduced liver targeting
RNA- and DNA-driven evolution to help improve the efficiency of identifying functional capsids

In this ophthalmology case study, our gene delivery team demonstrated a 30-fold improvement in AAV transduction compared to the benchmarks.

AAV nanobody platform

Achieving precise cell-type specificity is one of the defining challenges in gene therapy vector development to improve tropism and transduction. Our nanobody-displaying AAV platform is engineered on the principles of modular, rational retargeting, providing a differentiated and manufacturable foundation to accelerate your program.

Flexibility by design: The modular architecture decouples the targeting moiety from the capsid, so it can be adapted to other natural or synthetic capsids and nanobodies without rebuilding the vector from scratch.
Multi-serotype compatibility: Our proprietary platform is validated with AAV2, AAV5, and AAV9 for compatibility across multiple nanobodies, so you have a flexible starting point regardless of your target indication.
Fusion protein-based display: The platform’s nanobody is genetically encoded directly within the capsid proteins to support single-step downstream processing and precise control over ligand presentation to streamline your CMC workflow.
Established and scalable manufacturing: A robust production process is already in place, reducing development risk and compressing timelines from concept to application.
IP-protected and licensable: A patent-pending platform with exclusive commercialisation rights provides you with a defensible foundation for licensing and downstream development.

Representative microscopy pictures of NGN2 and AD2 neuronal cells transduced with the analyzed AAV set expressing eGFP under different promoters. An increase of reporter fluorescence is visible in wells transduced with VP3-Nb constructs.

What our partners value from us

Close collaboration with exchange of know-how from both parties resulting in joint decision making to deliver customized programs focused on the client's end goal.
Our established partnership network with commercial and academic leaders in the field of AAVs.
Our capabilities in gene editing and delivery, including over 20 years of innovation and experience in viral vector manufacturing.

Please contact us to learn more about our adeno-associated virus capsid development capabilities and to speak to our licensing team.

A commercial license is required for any clinical or commercial application involving AAVs developed using Revvity technologies.